Capital Bank & Trust Co Has $92.50 Million Position in AstraZeneca plc (AZN)
Capital Bank & Trust Co increased its position in AstraZeneca plc (NYSE:AZN) by 2.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,730,208 shares of the company’s stock after buying an additional 57,353 shares during the quarter. AstraZeneca accounts for approximately 1.2% of Capital Bank & Trust Co’s holdings, making the stock its 27th biggest holding. Capital Bank & Trust Co owned about 0.11% of AstraZeneca worth $92,499,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. IFP Advisors Inc increased its position in AstraZeneca by 28.5% during the 2nd quarter. IFP Advisors Inc now owns 14,570 shares of the company’s stock valued at $497,000 after purchasing an additional 3,235 shares during the period. Trexquant Investment LP purchased a new position in AstraZeneca during the 2nd quarter valued at $450,000. Berkeley Capital Partners LLC increased its position in AstraZeneca by 3.7% during the 2nd quarter. Berkeley Capital Partners LLC now owns 34,644 shares of the company’s stock valued at $1,181,000 after purchasing an additional 1,233 shares during the period. Garrison Financial Corp increased its position in AstraZeneca by 0.5% during the 2nd quarter. Garrison Financial Corp now owns 18,058 shares of the company’s stock valued at $616,000 after purchasing an additional 86 shares during the period. Finally, Pinnacle Financial Partners Inc. boosted its holdings in shares of AstraZeneca by 2.5% during the 2nd quarter. Pinnacle Financial Partners Inc. now owns 9,233 shares of the company’s stock valued at $314,000 after buying an additional 229 shares in the last quarter. 14.75% of the stock is currently owned by institutional investors.
A number of analysts have recently commented on AZN shares. Natixis upgraded shares of AstraZeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, September 6th. Leerink Swann boosted their target price on shares of AstraZeneca from $31.00 to $34.00 and gave the company a “market perform” rating in a report on Monday, October 23rd. Credit Suisse Group upgraded shares of AstraZeneca from a “neutral” rating to an “outperform” rating in a report on Monday, October 16th. Argus restated a “buy” rating and set a $35.00 target price on shares of AstraZeneca in a report on Friday, September 1st. Finally, BMO Capital Markets set a $38.00 target price on shares of AstraZeneca and gave the company a “buy” rating in a report on Tuesday, October 31st. Four research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $34.20.
AstraZeneca plc (NYSE AZN) opened at $32.74 on Friday. The stock has a market cap of $82,894.28, a PE ratio of 7.81, a P/E/G ratio of 2.98 and a beta of 0.72. AstraZeneca plc has a one year low of $26.51 and a one year high of $35.60. The company has a debt-to-equity ratio of 1.09, a current ratio of 0.94 and a quick ratio of 0.72.
AstraZeneca (NYSE:AZN) last announced its quarterly earnings results on Thursday, November 9th. The company reported $1.12 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.57 by $0.55. The company had revenue of $6.23 billion for the quarter, compared to analysts’ expectations of $6 billion. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. AstraZeneca’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.32 EPS. analysts expect that AstraZeneca plc will post 1.87 earnings per share for the current year.
WARNING: “Capital Bank & Trust Co Has $92.50 Million Position in AstraZeneca plc (AZN)” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.watchlistnews.com/capital-bank-trust-co-has-92-50-million-position-in-astrazeneca-plc-azn/1755514.html.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.